Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572268 | 0.87 | PTGES (0.48) | PTGESKMT2AMEN1HSD11B1POLB | |
| SCHEMBL3567949 | 0.79 | PTGES (0.52) | PTGESRAB9AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3572573 | 0.79 | PTGES (0.56) | CYP2C9PTGESKMT2AMEN1RAB9A | |
| SCHEMBL3578959 | 0.78 | PTGES (0.77) | CYP2C9PTGESKMT2AMEN1POLB | |
| SCHEMBL3001562 | 0.77 | PTGES (0.54) | CYP2C9PTGESKMT2AMEN1RAB9A | |
| SCHEMBL18501705 | 0.74 | TSHR (0.69) | KMT2AMEN1HSD11B1POLBALDH1A1 | |
| SCHEMBL3573984 | 0.72 | PTGES (0.67) | PTGESALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL3572427 | 0.71 | PTGES (0.62) | CYP2C9PTGESKMT2AMEN1RAB9A | |
| SCHEMBL7136125 | 0.70 | NOD2 (0.55) | CYP2C9KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL12169362 | 0.70 | LMNA (0.73) | KMT2AMEN1HSD11B1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705023-B2 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2010-04-27 | — | — | US | disclosed |
| EP-1778632-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | PTGS1, IDO1, PTGES | CYP2C9 131/4885PTGES 3/4885KMT2A 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.